The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Synopsis
Adalimumab, sold under the trade name Humira among others, is a medication used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, chronic psoriasis, hidradenitis suppurativa, and juvenile idiopathic arthritis.
The global Adalimumab market was valued at US$ 146 million in 2023 and is anticipated to reach US$ 192.7 million by 2030, witnessing a CAGR of 4.5% during the forecast period 2024-2030.
Adalimumab is a widely used biologic medication that belongs to the class of tumor necrosis factor (TNF) inhibitors. It is primarily prescribed for the treatment of autoimmune diseases such as rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, and ulcerative colitis. Autoimmune diseases are on the rise globally, affecting millions of people. Adalimumab is one of the leading treatment options for these conditions, driving the demand for the medication. Improved awareness and diagnosis of autoimmune diseases have led to an increased demand for effective treatment options like adalimumab. Biologic drugs, including adalimumab, have gained popularity due to their targeted treatment approach and potential for better disease management. Patients are increasingly opting for these medications over conventional therapies, driving the market growth of adalimumab. Adalimumab has received approvals for an expanding range of indications, including pediatric use and additional inflammatory conditions. The availability of more indications and treatment options has expanded the addressable market for adalimumab. The expiration of adalimumab's patent in various regions has opened the doors for the entry of biosimilar versions of the drug. Biosimilars offer competitive pricing, increasing market accessibility and potentially driving the overall market growth. Reimbursement policies and insurance coverage play a significant role in the adoption and market drive of adalimumab. Favorable policies and coverage encourage patient access and contribute to the growth of the market. Advances in drug delivery systems, such as autoinjectors and pre-filled syringes, have increased the convenience and ease of administration for patients using adalimumab, enhancing its market drive.
This report aims to provide a comprehensive presentation of the global market for Adalimumab, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Adalimumab.
Report Scope
The Adalimumab market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Adalimumab market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Adalimumab manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AbbVie
Amgen
Sandoz
Boehringer Ingelheim
Mylan
Biogen
Aark Pharmaceuticals
Amgevita
Delphis Pharma
Segment by Type
Adalimumab
Adalimumab Biosimilar
Segment by Application
Adults
Children
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Adalimumab manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Adalimumab in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Adalimumab, sold under the trade name Humira among others, is a medication used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, chronic psoriasis, hidradenitis suppurativa, and juvenile idiopathic arthritis.
The global Adalimumab market was valued at US$ 146 million in 2023 and is anticipated to reach US$ 192.7 million by 2030, witnessing a CAGR of 4.5% during the forecast period 2024-2030.
Adalimumab is a widely used biologic medication that belongs to the class of tumor necrosis factor (TNF) inhibitors. It is primarily prescribed for the treatment of autoimmune diseases such as rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, and ulcerative colitis. Autoimmune diseases are on the rise globally, affecting millions of people. Adalimumab is one of the leading treatment options for these conditions, driving the demand for the medication. Improved awareness and diagnosis of autoimmune diseases have led to an increased demand for effective treatment options like adalimumab. Biologic drugs, including adalimumab, have gained popularity due to their targeted treatment approach and potential for better disease management. Patients are increasingly opting for these medications over conventional therapies, driving the market growth of adalimumab. Adalimumab has received approvals for an expanding range of indications, including pediatric use and additional inflammatory conditions. The availability of more indications and treatment options has expanded the addressable market for adalimumab. The expiration of adalimumab's patent in various regions has opened the doors for the entry of biosimilar versions of the drug. Biosimilars offer competitive pricing, increasing market accessibility and potentially driving the overall market growth. Reimbursement policies and insurance coverage play a significant role in the adoption and market drive of adalimumab. Favorable policies and coverage encourage patient access and contribute to the growth of the market. Advances in drug delivery systems, such as autoinjectors and pre-filled syringes, have increased the convenience and ease of administration for patients using adalimumab, enhancing its market drive.
This report aims to provide a comprehensive presentation of the global market for Adalimumab, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Adalimumab.
Report Scope
The Adalimumab market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Adalimumab market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Adalimumab manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AbbVie
Amgen
Sandoz
Boehringer Ingelheim
Mylan
Biogen
Aark Pharmaceuticals
Amgevita
Delphis Pharma
Segment by Type
Adalimumab
Adalimumab Biosimilar
Segment by Application
Adults
Children
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Adalimumab manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Adalimumab in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Adalimumab Market Overview
1.1 Product Overview and Scope of Adalimumab
1.2 Adalimumab Segment by Type
1.2.1 Global Adalimumab Market Value Comparison by Type (2024-2030)
1.2.2 Adalimumab
1.2.3 Adalimumab Biosimilar
1.3 Adalimumab Segment by Application
1.3.1 Global Adalimumab Market Value by Application: (2024-2030)
1.3.2 Adults
1.3.3 Children
1.4 Global Adalimumab Market Size Estimates and Forecasts
1.4.1 Global Adalimumab Revenue 2019-2030
1.4.2 Global Adalimumab Sales 2019-2030
1.4.3 Global Adalimumab Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Adalimumab Market Competition by Manufacturers
2.1 Global Adalimumab Sales Market Share by Manufacturers (2019-2024)
2.2 Global Adalimumab Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Adalimumab Average Price by Manufacturers (2019-2024)
2.4 Global Adalimumab Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Adalimumab, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Adalimumab, Product Type & Application
2.7 Adalimumab Market Competitive Situation and Trends
2.7.1 Adalimumab Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Adalimumab Players Market Share by Revenue
2.7.3 Global Adalimumab Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Adalimumab Retrospective Market Scenario by Region
3.1 Global Adalimumab Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Adalimumab Global Adalimumab Sales by Region: 2019-2030
3.2.1 Global Adalimumab Sales by Region: 2019-2024
3.2.2 Global Adalimumab Sales by Region: 2025-2030
3.3 Global Adalimumab Global Adalimumab Revenue by Region: 2019-2030
3.3.1 Global Adalimumab Revenue by Region: 2019-2024
3.3.2 Global Adalimumab Revenue by Region: 2025-2030
3.4 North America Adalimumab Market Facts & Figures by Country
3.4.1 North America Adalimumab Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Adalimumab Sales by Country (2019-2030)
3.4.3 North America Adalimumab Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Adalimumab Market Facts & Figures by Country
3.5.1 Europe Adalimumab Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Adalimumab Sales by Country (2019-2030)
3.5.3 Europe Adalimumab Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Adalimumab Market Facts & Figures by Country
3.6.1 Asia Pacific Adalimumab Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Adalimumab Sales by Country (2019-2030)
3.6.3 Asia Pacific Adalimumab Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Adalimumab Market Facts & Figures by Country
3.7.1 Latin America Adalimumab Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Adalimumab Sales by Country (2019-2030)
3.7.3 Latin America Adalimumab Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Adalimumab Market Facts & Figures by Country
3.8.1 Middle East and Africa Adalimumab Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Adalimumab Sales by Country (2019-2030)
3.8.3 Middle East and Africa Adalimumab Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Adalimumab Sales by Type (2019-2030)
4.1.1 Global Adalimumab Sales by Type (2019-2024)
4.1.2 Global Adalimumab Sales by Type (2025-2030)
4.1.3 Global Adalimumab Sales Market Share by Type (2019-2030)
4.2 Global Adalimumab Revenue by Type (2019-2030)
4.2.1 Global Adalimumab Revenue by Type (2019-2024)
4.2.2 Global Adalimumab Revenue by Type (2025-2030)
4.2.3 Global Adalimumab Revenue Market Share by Type (2019-2030)
4.3 Global Adalimumab Price by Type (2019-2030)
5 Segment by Application
5.1 Global Adalimumab Sales by Application (2019-2030)
5.1.1 Global Adalimumab Sales by Application (2019-2024)
5.1.2 Global Adalimumab Sales by Application (2025-2030)
5.1.3 Global Adalimumab Sales Market Share by Application (2019-2030)
5.2 Global Adalimumab Revenue by Application (2019-2030)
5.2.1 Global Adalimumab Revenue by Application (2019-2024)
5.2.2 Global Adalimumab Revenue by Application (2025-2030)
5.2.3 Global Adalimumab Revenue Market Share by Application (2019-2030)
5.3 Global Adalimumab Price by Application (2019-2030)
6 Key Companies Profiled
6.1 AbbVie
6.1.1 AbbVie Corporation Information
6.1.2 AbbVie Description and Business Overview
6.1.3 AbbVie Adalimumab Sales, Revenue and Gross Margin (2019-2024)
6.1.4 AbbVie Adalimumab Product Portfolio
6.1.5 AbbVie Recent Developments/Updates
6.2 Amgen
6.2.1 Amgen Corporation Information
6.2.2 Amgen Description and Business Overview
6.2.3 Amgen Adalimumab Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Amgen Adalimumab Product Portfolio
6.2.5 Amgen Recent Developments/Updates
6.3 Sandoz
6.3.1 Sandoz Corporation Information
6.3.2 Sandoz Description and Business Overview
6.3.3 Sandoz Adalimumab Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Sandoz Adalimumab Product Portfolio
6.3.5 Sandoz Recent Developments/Updates
6.4 Boehringer Ingelheim
6.4.1 Boehringer Ingelheim Corporation Information
6.4.2 Boehringer Ingelheim Description and Business Overview
6.4.3 Boehringer Ingelheim Adalimumab Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Boehringer Ingelheim Adalimumab Product Portfolio
6.4.5 Boehringer Ingelheim Recent Developments/Updates
6.5 Mylan
6.5.1 Mylan Corporation Information
6.5.2 Mylan Description and Business Overview
6.5.3 Mylan Adalimumab Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Mylan Adalimumab Product Portfolio
6.5.5 Mylan Recent Developments/Updates
6.6 Biogen
6.6.1 Biogen Corporation Information
6.6.2 Biogen Description and Business Overview
6.6.3 Biogen Adalimumab Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Biogen Adalimumab Product Portfolio
6.6.5 Biogen Recent Developments/Updates
6.7 Aark Pharmaceuticals
6.6.1 Aark Pharmaceuticals Corporation Information
6.6.2 Aark Pharmaceuticals Description and Business Overview
6.6.3 Aark Pharmaceuticals Adalimumab Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Aark Pharmaceuticals Adalimumab Product Portfolio
6.7.5 Aark Pharmaceuticals Recent Developments/Updates
6.8 Amgevita
6.8.1 Amgevita Corporation Information
6.8.2 Amgevita Description and Business Overview
6.8.3 Amgevita Adalimumab Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Amgevita Adalimumab Product Portfolio
6.8.5 Amgevita Recent Developments/Updates
6.9 Delphis Pharma
6.9.1 Delphis Pharma Corporation Information
6.9.2 Delphis Pharma Description and Business Overview
6.9.3 Delphis Pharma Adalimumab Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Delphis Pharma Adalimumab Product Portfolio
6.9.5 Delphis Pharma Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Adalimumab Industry Chain Analysis
7.2 Adalimumab Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Adalimumab Production Mode & Process
7.4 Adalimumab Sales and Marketing
7.4.1 Adalimumab Sales Channels
7.4.2 Adalimumab Distributors
7.5 Adalimumab Customers
8 Adalimumab Market Dynamics
8.1 Adalimumab Industry Trends
8.2 Adalimumab Market Drivers
8.3 Adalimumab Market Challenges
8.4 Adalimumab Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Adalimumab Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Adalimumab Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global Adalimumab Market Competitive Situation by Manufacturers in 2023
Table 4. Global Adalimumab Sales (K Units) of Key Manufacturers (2019-2024)
Table 5. Global Adalimumab Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Adalimumab Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Adalimumab Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Adalimumab Average Price (USD/Unit) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Adalimumab, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Adalimumab, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Adalimumab, Product Type & Application
Table 12. Global Key Manufacturers of Adalimumab, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Adalimumab by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Adalimumab as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Adalimumab Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Adalimumab Sales by Region (2019-2024) & (K Units)
Table 18. Global Adalimumab Sales Market Share by Region (2019-2024)
Table 19. Global Adalimumab Sales by Region (2025-2030) & (K Units)
Table 20. Global Adalimumab Sales Market Share by Region (2025-2030)
Table 21. Global Adalimumab Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Adalimumab Revenue Market Share by Region (2019-2024)
Table 23. Global Adalimumab Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Adalimumab Revenue Market Share by Region (2025-2030)
Table 25. North America Adalimumab Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Adalimumab Sales by Country (2019-2024) & (K Units)
Table 27. North America Adalimumab Sales by Country (2025-2030) & (K Units)
Table 28. North America Adalimumab Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Adalimumab Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Adalimumab Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Adalimumab Sales by Country (2019-2024) & (K Units)
Table 32. Europe Adalimumab Sales by Country (2025-2030) & (K Units)
Table 33. Europe Adalimumab Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Adalimumab Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Adalimumab Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Adalimumab Sales by Region (2019-2024) & (K Units)
Table 37. Asia Pacific Adalimumab Sales by Region (2025-2030) & (K Units)
Table 38. Asia Pacific Adalimumab Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Adalimumab Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Adalimumab Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Adalimumab Sales by Country (2019-2024) & (K Units)
Table 42. Latin America Adalimumab Sales by Country (2025-2030) & (K Units)
Table 43. Latin America Adalimumab Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Adalimumab Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Adalimumab Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Adalimumab Sales by Country (2019-2024) & (K Units)
Table 47. Middle East & Africa Adalimumab Sales by Country (2025-2030) & (K Units)
Table 48. Middle East & Africa Adalimumab Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Adalimumab Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Adalimumab Sales (K Units) by Type (2019-2024)
Table 51. Global Adalimumab Sales (K Units) by Type (2025-2030)
Table 52. Global Adalimumab Sales Market Share by Type (2019-2024)
Table 53. Global Adalimumab Sales Market Share by Type (2025-2030)
Table 54. Global Adalimumab Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Adalimumab Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Adalimumab Revenue Market Share by Type (2019-2024)
Table 57. Global Adalimumab Revenue Market Share by Type (2025-2030)
Table 58. Global Adalimumab Price (USD/Unit) by Type (2019-2024)
Table 59. Global Adalimumab Price (USD/Unit) by Type (2025-2030)
Table 60. Global Adalimumab Sales (K Units) by Application (2019-2024)
Table 61. Global Adalimumab Sales (K Units) by Application (2025-2030)
Table 62. Global Adalimumab Sales Market Share by Application (2019-2024)
Table 63. Global Adalimumab Sales Market Share by Application (2025-2030)
Table 64. Global Adalimumab Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Adalimumab Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Adalimumab Revenue Market Share by Application (2019-2024)
Table 67. Global Adalimumab Revenue Market Share by Application (2025-2030)
Table 68. Global Adalimumab Price (USD/Unit) by Application (2019-2024)
Table 69. Global Adalimumab Price (USD/Unit) by Application (2025-2030)
Table 70. AbbVie Corporation Information
Table 71. AbbVie Description and Business Overview
Table 72. AbbVie Adalimumab Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 73. AbbVie Adalimumab Product
Table 74. AbbVie Recent Developments/Updates
Table 75. Amgen Corporation Information
Table 76. Amgen Description and Business Overview
Table 77. Amgen Adalimumab Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 78. Amgen Adalimumab Product
Table 79. Amgen Recent Developments/Updates
Table 80. Sandoz Corporation Information
Table 81. Sandoz Description and Business Overview
Table 82. Sandoz Adalimumab Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 83. Sandoz Adalimumab Product
Table 84. Sandoz Recent Developments/Updates
Table 85. Boehringer Ingelheim Corporation Information
Table 86. Boehringer Ingelheim Description and Business Overview
Table 87. Boehringer Ingelheim Adalimumab Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 88. Boehringer Ingelheim Adalimumab Product
Table 89. Boehringer Ingelheim Recent Developments/Updates
Table 90. Mylan Corporation Information
Table 91. Mylan Description and Business Overview
Table 92. Mylan Adalimumab Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 93. Mylan Adalimumab Product
Table 94. Mylan Recent Developments/Updates
Table 95. Biogen Corporation Information
Table 96. Biogen Description and Business Overview
Table 97. Biogen Adalimumab Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 98. Biogen Adalimumab Product
Table 99. Biogen Recent Developments/Updates
Table 100. Aark Pharmaceuticals Corporation Information
Table 101. Aark Pharmaceuticals Description and Business Overview
Table 102. Aark Pharmaceuticals Adalimumab Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 103. Aark Pharmaceuticals Adalimumab Product
Table 104. Aark Pharmaceuticals Recent Developments/Updates
Table 105. Amgevita Corporation Information
Table 106. Amgevita Description and Business Overview
Table 107. Amgevita Adalimumab Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 108. Amgevita Adalimumab Product
Table 109. Amgevita Recent Developments/Updates
Table 110. Delphis Pharma Corporation Information
Table 111. Delphis Pharma Description and Business Overview
Table 112. Delphis Pharma Adalimumab Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 113. Delphis Pharma Adalimumab Product
Table 114. Delphis Pharma Recent Developments/Updates
Table 115. Key Raw Materials Lists
Table 116. Raw Materials Key Suppliers Lists
Table 117. Adalimumab Distributors List
Table 118. Adalimumab Customers List
Table 119. Adalimumab Market Trends
Table 120. Adalimumab Market Drivers
Table 121. Adalimumab Market Challenges
Table 122. Adalimumab Market Restraints
Table 123. Research Programs/Design for This Report
Table 124. Key Data Information from Secondary Sources
Table 125. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Adalimumab
Figure 2. Global Adalimumab Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Adalimumab Market Share by Type in 2023 & 2030
Figure 4. Adalimumab Product Picture
Figure 5. Adalimumab Biosimilar Product Picture
Figure 6. Global Adalimumab Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 7. Global Adalimumab Market Share by Application in 2023 & 2030
Figure 8. Adults
Figure 9. Children
Figure 10. Global Adalimumab Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 11. Global Adalimumab Market Size (2019-2030) & (US$ Million)
Figure 12. Global Adalimumab Sales (2019-2030) & (K Units)
Figure 13. Global Adalimumab Average Price (USD/Unit) & (2019-2030)
Figure 14. Adalimumab Report Years Considered
Figure 15. Adalimumab Sales Share by Manufacturers in 2023
Figure 16. Global Adalimumab Revenue Share by Manufacturers in 2023
Figure 17. The Global 5 and 10 Largest Adalimumab Players: Market Share by Revenue in 2023
Figure 18. Adalimumab Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 19. Global Adalimumab Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 20. North America Adalimumab Sales Market Share by Country (2019-2030)
Figure 21. North America Adalimumab Revenue Market Share by Country (2019-2030)
Figure 22. U.S. Adalimumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 23. Canada Adalimumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 24. Europe Adalimumab Sales Market Share by Country (2019-2030)
Figure 25. Europe Adalimumab Revenue Market Share by Country (2019-2030)
Figure 26. Germany Adalimumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 27. France Adalimumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 28. U.K. Adalimumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 29. Italy Adalimumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 30. Russia Adalimumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. Asia Pacific Adalimumab Sales Market Share by Region (2019-2030)
Figure 32. Asia Pacific Adalimumab Revenue Market Share by Region (2019-2030)
Figure 33. China Adalimumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 34. Japan Adalimumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 35. South Korea Adalimumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. India Adalimumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. Australia Adalimumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. Taiwan Adalimumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. Indonesia Adalimumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. Thailand Adalimumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. Malaysia Adalimumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Philippines Adalimumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. Latin America Adalimumab Sales Market Share by Country (2019-2030)
Figure 44. Latin America Adalimumab Revenue Market Share by Country (2019-2030)
Figure 45. Mexico Adalimumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 46. Brazil Adalimumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 47. Argentina Adalimumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 48. Middle East & Africa Adalimumab Sales Market Share by Country (2019-2030)
Figure 49. Middle East & Africa Adalimumab Revenue Market Share by Country (2019-2030)
Figure 50. Turkey Adalimumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 51. Saudi Arabia Adalimumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 52. U.A.E Adalimumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 53. Global Sales Market Share of Adalimumab by Type (2019-2030)
Figure 54. Global Revenue Market Share of Adalimumab by Type (2019-2030)
Figure 55. Global Adalimumab Price (USD/Unit) by Type (2019-2030)
Figure 56. Global Sales Market Share of Adalimumab by Application (2019-2030)
Figure 57. Global Revenue Market Share of Adalimumab by Application (2019-2030)
Figure 58. Global Adalimumab Price (USD/Unit) by Application (2019-2030)
Figure 59. Adalimumab Value Chain
Figure 60. Adalimumab Production Process
Figure 61. Channels of Distribution (Direct Vs Distribution)
Figure 62. Distributors Profiles
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
